Premium Modified GRF (1-29) 5mg (aka CJC-1295 w/o DAC)
€32.50
- Description
- Benefits
- Risks
- Additional information
- Research
Description
Premium Modified GRF 1-29 (also known as CJC-1295 without DAC) is a high-purity synthetic analogue of growth hormone-releasing hormone (GHRH), developed for research into growth hormone (GH) pulsatility, endocrine signalling, and short-acting peptide dynamics.
Unlike DAC-modified variants, this peptide is designed for short-duration activity, making it highly suitable for experimental models aiming to replicate natural GH release patterns and physiological hormone rhythms.
This premium-grade variant is tailored for research requiring enhanced purity, batch consistency, and reproducibility, particularly in advanced laboratory environments across Ireland and Europe.
In controlled research settings, Modified GRF 1-29 interacts with GHRH receptors located in the pituitary gland, stimulating time-dependent growth hormone release in alignment with natural endocrine behaviour.
Common research applications include:
- Growth hormone pulsatility and secretion pattern studies
- GHRH receptor activation and endocrine signalling
- GH/IGF-1 axis research
- Short-acting peptide pharmacokinetics and timing
This product is supplied as a high-purity research peptide, intended strictly for scientific and laboratory use.
Disclaimer: This product is strictly for research purposes only and is not for human consumption.
Technical Information – Premium Modified GRF 1-29
| Specification | Details |
|---|---|
| Product Name | Premium Modified GRF 1-29 (CJC-1295 without DAC) |
| Compound Type | Synthetic GHRH analogue peptide |
| Functional Class | Growth hormone-releasing hormone analogue |
| Mechanism of Action | Activates GHRH receptors to stimulate GH release |
| Biological Targets | Pituitary gland, GH/IGF-1 axis |
| Activity Profile | Short-acting (no DAC modification) |
| Format | Lyophilised powder |
| Purity | High-purity research grade |
| Storage | Refrigerated (2–8°C, protected from light) |
| Application | Laboratory research use only |
* Images for illustration purposes only
Further Refrences: PubChem Entry
Researched Benefits & Focus Areas – Premium Modified GRF 1-29
1. Pulsatile Growth Hormone (GH) Release Research
Premium Modified GRF 1-29 has been studied for:
- Stimulation of GH release in pulsatile patterns
- Investigation of natural hormone secretion rhythms
- Analysis of pituitary gland signalling behaviour
Reference basis: Derived from endocrinology research examining GHRH analogues and physiological GH release patterns.
2. GHRH Receptor Activation
Research has explored:
- Binding to growth hormone-releasing hormone receptors
- Activation of pituitary GH secretion pathways
- Interaction with endocrine signalling systems
Reference basis: Based on biochemical studies investigating GHRH receptor signalling and peptide-receptor interactions.
3. Short-Acting Peptide Dynamics
This peptide is specifically designed for:
- Short-duration activity in experimental models
- Simulation of natural endocrine timing and rhythms
- Research into controlled hormonal response patterns
Reference basis: Supported by pharmacokinetic studies comparing short-acting versus long-acting peptide analogues.
4. High-Purity & Reproducibility Focus
The premium variant supports:
- Consistent peptide performance across studies
- Improved reproducibility in experimental models
- Enhanced purity for controlled laboratory conditions
Reference basis: Based on laboratory standards emphasising purity and consistency in peptide-based research.
Disclaimer: These are research-based findings only. This product is not intended for human use or consumption.
Researched Risks & Considerations – Premium Modified GRF 1-29
1. Hormonal System Influence
- May significantly affect growth hormone levels
- Potential for endocrine imbalance in research models
Reference basis: Based on studies examining GH regulation and hormonal feedback systems.
2. Short Duration of Action
- Requires precise timing in experimental protocols
- May lead to variable outcomes depending on administration patterns
Reference basis: Derived from research into short-acting peptide pharmacokinetics.
3. Endocrine Feedback Effects
- May influence natural hormonal feedback loops
- Potential for overstimulation or suppression of signalling pathways
Reference basis: Based on studies examining GH/IGF-1 axis regulation and endocrine feedback mechanisms.
4. Limited Long-Term Research
- Lack of extensive long-term data
- Primarily studied in controlled laboratory environments
Reference basis: Reflects the current stage of GHRH analogue research.
Disclaimer: These risks are based on available research data only. This product is strictly a research peptide and not for human consumption.
Additional information
| Weight | 23 kg |
|---|---|
| Dimensions | 12 × 23 × 56 cm |
| Quantity | 1 Vial, 1 Kit (10 Vials) |
Related Products
FEATURED PRODUCTS
BEST SELLING PRODUCTS
LATEST PRODUCTS
TOP RATED PRODUCTS